Mercor’s Brendan Foody calls out Sequoia, accusing it of ‘dual-pricing’ valuation tricks

Founders Challenge VC Valuation Tactics

Mercor co-founder Brendan Foody has publicly accused venture capital firm Sequoia of promoting a 'scam' involving dual-tranche investments that create misleadingly high headline valuations. This accusation, made on the social platform X, has ignited a broader discussion among founders and investors, casting a harsh light on the valuation mechanics powering the current AI boom and questioning the transparency of elite VC firms.

The Mechanics of Dual-Pricing

The practice, which Foody dubbed the 'sequoia scam,' involves structuring a single funding round into two distinct parts with different valuations. This allows a lead investor to secure a significant stake at a favorable price while simultaneously generating market hype with a much higher public number. While not exclusive to Sequoia, the firm's involvement has drawn significant attention. A Sequoia partner, Shaun Maguire, responded by framing the practice as a market reality for participating in hot deals without overpaying on the entire amount.

• A lead VC invests a large sum at a lower, preferential valuation.
• A much smaller sum is invested at a significantly higher valuation.
• The higher number is announced as the 'headline' valuation, creating a perception of massive success.
• The lead investor's actual average entry price remains substantially lower, as seen in deals with startups like Serval and Aaru.

Ecosystem-Wide Implications

This valuation strategy has significant ripple effects. For employees, independent 409A appraisals are meant to set fair stock option prices, but these valuations are known to skew low. Angel investors, however, lack this buffer and may invest based on an inflated headline figure. The tactic is part of a wider trend of perception management, which includes overstating metrics like Annual Recurring Revenue (ARR). Niko Bonatsos, founder of Verdict Capital, noted that ARR figures are sometimes manipulated by annualizing a single day's revenue, making it difficult to gauge a startup's true financial health.

The public call-outs of dual-pricing and ARR inflation signal a growing tension between founders and VCs over valuation transparency. As capital becomes more discerning, the 'growth-at-all-costs' narrative is being challenged, forcing a potential market correction where actual financial health and fair-dealing will outweigh manufactured hype.